

Valera Pharmaceuticals Inc  
Form 15-12G  
April 18, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE**  
**REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: 000-51768

**VALERA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**7 Clarke Drive, Cranbury, NJ 08512-3617**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common stock, par value \$0.001 per share**

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)(i)	x	Rule 12h-3(b)(1)(i)	x
Rule 12g-4(a)(1)(ii)	..	Rule 12h-3(b)(1)(ii)	..
Rule 12g-4(a)(2)(i)	..	Rule 12h-3(b)(2)(i)	..
Rule 12g-4(a)(2)(ii)	..	Rule 12h-3(b)(2)(ii)	..
		Rule 15d-6	..

Approximate number of holders of record as of the certification or notice date: one (1).

Pursuant to the requirements of the Securities Exchange Act of 1934, Valera Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Valera Pharmaceuticals, Inc.

Edgar Filing: Valera Pharmaceuticals Inc - Form 15-12G

Date: April 18, 2007

By: /s/ Andrew T. Drechsler  
Name: Andrew T. Drechsler  
Title: Chief Financial Officer